14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:CATB
Delisted

Catabasis Pharmaceuticals Stock Price (Quote)

$3.36
+0.195 (+6.16%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $3.02 $6.17 Friday, 27th May 2022 CATB stock ended at $3.36. This is 6.16% more than the trading day before Thursday, 26th May 2022. During the day the stock fluctuated 6.65% from a day low at $3.16 to a day high of $3.37.
90 days $3.02 $7.25
52 weeks $1.20 $10.26

Historical Catabasis Pharmaceuticals prices

Date Open High Low Close Volume
Dec 04, 2019 $5.76 $6.08 $5.66 $6.04 100 336
Dec 03, 2019 $6.23 $6.43 $5.69 $5.81 172 664
Dec 02, 2019 $5.73 $6.18 $5.70 $6.10 139 885
Nov 29, 2019 $5.35 $5.75 $5.35 $5.66 65 662
Nov 27, 2019 $4.98 $5.50 $4.98 $5.32 276 156
Nov 26, 2019 $4.96 $5.05 $4.89 $5.00 49 526
Nov 25, 2019 $4.95 $5.07 $4.95 $4.96 50 125
Nov 22, 2019 $4.99 $5.07 $4.92 $4.96 21 168
Nov 21, 2019 $4.95 $5.09 $4.83 $4.99 88 698
Nov 20, 2019 $5.03 $5.30 $4.93 $4.93 100 247
Nov 19, 2019 $4.96 $5.31 $4.92 $4.97 175 543
Nov 18, 2019 $5.03 $5.12 $4.92 $4.99 78 231
Nov 15, 2019 $5.34 $5.34 $5.06 $5.07 53 869
Nov 14, 2019 $5.35 $5.38 $5.26 $5.26 36 442
Nov 13, 2019 $5.44 $5.44 $5.24 $5.31 98 448
Nov 12, 2019 $5.45 $5.48 $5.28 $5.45 73 961
Nov 11, 2019 $5.14 $5.44 $5.02 $5.35 105 830
Nov 08, 2019 $5.23 $5.45 $5.03 $5.12 69 301
Nov 07, 2019 $5.48 $5.48 $5.10 $5.29 86 735
Nov 06, 2019 $5.25 $5.42 $5.15 $5.19 54 316
Nov 05, 2019 $5.23 $5.49 $5.23 $5.27 40 321
Nov 04, 2019 $5.56 $5.64 $5.18 $5.22 46 475
Nov 01, 2019 $5.10 $5.59 $5.10 $5.58 89 138
Oct 31, 2019 $5.10 $5.15 $4.98 $5.07 54 968
Oct 30, 2019 $4.91 $5.13 $4.89 $5.10 39 766
Click to get the best stock tips daily for free!

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... CATB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT